Adherence to guidelines to prevent cardiovascular diseases: The lifelines cohort study

Netherlands Journal of Medicine

Volumn 73, Issue 7, 2015, Pages 316-323

  Balder, J W ^a   Scholtens, S ^a   de Vries, J K ^a   van Schie, L M ^a   Boekholdt, S M ^b   Hovingh, G K ^b   Kamphuisen, P W ^a   Kuivenhoven, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cardiovascular risk; Primary prevention; Risk assessment; Secondary prevention; Statins; Undertreatment; Underuse

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AWARENESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; POPULATION BASED CASE CONTROL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; QUESTIONNAIRE; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; ADOLESCENT; CARDIOVASCULAR DISEASES; PROSPECTIVE STUDY; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROSPECTIVE STUDIES; SECONDARY PREVENTION; YOUNG ADULT;

EID: 84940555822     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
3. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med. 2004;255:494-502.
4. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol. 2003;55:389-97.
5. Koopman C, Vaartjes I, Heintjes EM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur Heart J. 2013;34:3198-205.
6. Gamboa CM, Safford MM, Levitan EB, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348:108-14.
7. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-7.
8. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014;12:215-23.
9. Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011). Ned Tijdschr Geneeskd. 2012;156:A5104.
10. Saraf S, Ray KK. Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. Curr Opin Lipidol. 2014;25:413-7.
11. Stolk RP, Rosmalen JG, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol. 2008;23:67-74.
12. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499-510.
13. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-40.
14. van den Haak P, Heintjes E, Plat AW, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin. 2010;26:271-8.
15. Stranges S, Guallar E. Cardiovascular disease prevention in women: a rapidly evolving scenario. Nutr Metab Cardiovasc Dis. 2012;22:1013-8.
16. Hart RG, Eikelboom JW, Pearce LA. Sex, stroke, and atrial fibrillation. Arch Neurol. 2012;69:1641-3.